1. Home
  2. KBH vs CRSP Comparison

KBH vs CRSP Comparison

Compare KBH & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KBH
  • CRSP
  • Stock Information
  • Founded
  • KBH 1957
  • CRSP 2013
  • Country
  • KBH United States
  • CRSP Switzerland
  • Employees
  • KBH N/A
  • CRSP N/A
  • Industry
  • KBH Homebuilding
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KBH Consumer Discretionary
  • CRSP Health Care
  • Exchange
  • KBH Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • KBH 3.8B
  • CRSP 4.2B
  • IPO Year
  • KBH 1987
  • CRSP 2016
  • Fundamental
  • Price
  • KBH $55.60
  • CRSP $56.62
  • Analyst Decision
  • KBH Buy
  • CRSP Buy
  • Analyst Count
  • KBH 12
  • CRSP 16
  • Target Price
  • KBH $67.04
  • CRSP $71.20
  • AVG Volume (30 Days)
  • KBH 1.9M
  • CRSP 3.7M
  • Earning Date
  • KBH 06-23-2025
  • CRSP 08-04-2025
  • Dividend Yield
  • KBH 1.78%
  • CRSP N/A
  • EPS Growth
  • KBH 0.48
  • CRSP N/A
  • EPS
  • KBH 7.59
  • CRSP N/A
  • Revenue
  • KBH $6,673,869,000.00
  • CRSP $37,675,000.00
  • Revenue This Year
  • KBH N/A
  • CRSP $30.25
  • Revenue Next Year
  • KBH N/A
  • CRSP $268.62
  • P/E Ratio
  • KBH $7.40
  • CRSP N/A
  • Revenue Growth
  • KBH 3.65
  • CRSP N/A
  • 52 Week Low
  • KBH $48.90
  • CRSP $30.04
  • 52 Week High
  • KBH $89.70
  • CRSP $63.68
  • Technical
  • Relative Strength Index (RSI)
  • KBH 57.28
  • CRSP 71.90
  • Support Level
  • KBH $52.34
  • CRSP $50.26
  • Resistance Level
  • KBH $57.38
  • CRSP $62.00
  • Average True Range (ATR)
  • KBH 1.98
  • CRSP 2.97
  • MACD
  • KBH 0.34
  • CRSP 0.93
  • Stochastic Oscillator
  • KBH 72.23
  • CRSP 71.76

About KBH KB Home

KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: